Obe-Cel Starts EMA Assessment in r/r B-ALL; April CHMP Agenda
On Monday, April 22, the CHMP Agenda for April was released. Of note, obe-cel (Autolus’s CD19 CAR-T) was included in the “Start of Procedure for New Application” section for the treatment of adult patients with r/r B-ALL.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.